Fragments: Past, present and future

Drug Discovery Today: Technologies

Volumn 7, Issue 3, 2010, Pages

  Whittaker, Mark ^a   Law, Richard J ^a   Ichihara, Osamu ^a   Hesterkamp, Thomas ^b   Hallett, David ^a  

^a EVOTEC UK LTD   (United Kingdom)

^b EVOTEC AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA SECRETASE; BETA SECRETASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE H4 RECEPTOR ANTAGONIST; LIGAND; PHOSPHODIESTERASE 10A INHIBITOR; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BIOASSAY; HIGH THROUGHPUT SCREENING; IC 50; LIGAND BINDING; NUCLEAR MAGNETIC RESONANCE; PROCESS OPTIMIZATION; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING; VIRTUAL REALITY; X RAY CRYSTALLOGRAPHY;

EID: 78650722321     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2010.11.007     Document Type: Review

References (48)

1. G. Chessari, and A.J. Woodhead From fragment to clinical candidate - a historical perspective Drug Discov. Today 14 2009 668 675
2. A.G. Coyne Drugging challenging targets using fragment-based approaches Curr. Opin. Chem. Biol. 14 2010 299 307
3. G.E. de Kloe Transforming fragments into candidates: small becomes big in medicinal chemistry Drug Discov. Today 14 2009 630 646
4. P.J. Hadjuk, and J. Greer A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discov. 6 2007 211 219
5. R. Law The multiple roles of computational chemistry in fragment-based drug design J. Comput. Aided Mol. Des. 23 2009 459 473
6. A.R. Leach Fragment screening: an introduction Mol. Biosyst. 2 2006 429 446
7. M. Congreve Recent developments in fragment-based drug discovery J. Med. Chem. 51 2008 3661 3680
8. P. Gund Three-dimensional pharmacophoric pattern searching Prog. Mol. Subcell. Biol. 5 1977 117 143
9. P.N. Craig, and H.M. Ebert Eleven years of structure retrieval using the SK&F fragment codes J. Chem. Doc. 9 1969 141 146
10. R.D. Cramer III Substructural analysis. A novel approach to the problem of drug design J. Med. Chem. 17 1974 533 535
11. W.F. Michne Hit-to-lead chemistry: a key element in new lead generation Pharmaceut. News 3 1996 19 21
12. S.B. Shuker Discovering high-affinity ligands for proteins: SAR by NMR Science 274 1996 1531 1534
13. P.J. Goodford A computational procedure for determining energetically favourable binding sites on biologically important macromolecules J. Med. Chem. 28 1985 849 857
14. C. Mattos, and D. Ringe Locating and characterizing binding sites on proteins Nat. Biotechnol. 14 1996 595 599
15. A. Miranker, and A. Karplus Functionality maps of binding sites: a multiple copy simultaneous search method Proteins 11 1991 29 34
16. C.L.M.J. Verlinde Fragment-based cocktail crystallography by the medical structural genomics of pathogenic protozoa consortium Curr. Top. Med. Chem. 9 2009 1678 1687
17. V.L. Nienaber Discovering novel ligands for macromolecules using X-ray crystallographic screening Nat. Biotechnol. 18 2000 1105 1108
18. J. Blaney Fragment-based lead discovery and optimization using X-ray crystallography, computational chemistry and high-throughput organic synthesis W. Jahnke, D.A. Erlanson, Fragment Based Approaches in Drug Discovery 2006 Wiley-VCH 55 66
19. M.J. Hartshorn Fragment-based lead discovery using X-ray crystallography J. Med. Chem. 48 2005 403 413
20. H.J. Boehm Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimisation. A promising alternative to random screening J. Med. Chem. 43 2000 2664 2674
21. R.E. Hubbard The SeeDs approach: integrating fragments into drug discovery Curr. Top. Med. Chem. 7 2007 1568 1581
22. M. Congreve A 'rule of three' for fragment-based lead discovery? Drug Discov.Today 8 2003 876 877
23. A.L. Hopkins Ligand efficiency: a useful metric for lead selection Drug Discov. Today 9 2004 430 431
24. T. Hesterkamp Fragment based drug discovery using fluorescence correlation spectroscopy techniques: challenges and solutions Curr. Top. Med. Chem. 7 2007 1582 1591
25. G.L. Card A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design Nat. Biotechnol. 23 2005 201 207
26. T. Hesterkamp, and M. Whittaker Fragment-based activity space: smaller is better Curr. Opin. Chem. Biol. 12 2008 260 268
27. A.A. Alex, and M.M. Flocco Fragment-based drug discovery: what has it achieved so far? Curr. Top. Med. Chem. 7 2007 1544 1567
28. J.J. Barker Fragment-based identification of Hsp90 inhibitors ChemMedChem 4 2009 963 966
29. J.J. Barker Discovery of a novel Hsp90 inhibitor by fragment linking ChemMedChem 5 2010 1697 1700
30. T. Neumann SPR-based fragment screening: advantages and applications Curr. Top. Med. Chem. 7 2007 1630 1642
31. S. Vanwetswinkel TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery Chem. Biol. 12 2005 207 216
32. M.T. Cancilla Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry Bioorg. Med. Chem. Lett. 18 2008 3978 3981
33. R. Godemann Fragment-based discovery of BACE1 inhibitors using functional assays Biochemistry 48 2009 10743 10751
34. J. Madden Fragment based discovery and optimisation of BACE1 inhibitors Bioorg. Med. Chem. Lett. 20 2010 5329 5333
35. J.S. Albert An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes Curr. Top. Med. Chem. 7 2007 1600 1629
36. L.R. McLean Discovery of covalent inhibitors for MIF tautomerase via cocrystal structures with phantom hits from virtual screening Bioorg. Med. Chem. Lett. 19 2009 6717 6720
37. L.R. McLean Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site Bioorg. Med. Chem. Lett. 20 2010 1821 1824
38. P.J. Hajduk, and J. Greer A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discov. 6 2007 211 219
39. K. Kitaura Fragment molecular orbital method: an approximate computational method for large molecules Chem. Phys. Lett. 313 1999 701 706 (Pubitemid 129556715)
40. E. Freire Do enthalpy and entropy distinguish first in class from best in class? Drug Discov. Today 13 2008 869 874
41. T.J. Crisman 'Virtual Fragment Linking': an approach to identify potent binders from low affinity fragment hits J. Med. Chem. 51 2008 2481 2491
42. Y. Tanrikulu Homology model adjustment and ligand screening with a pseudoreceptor of the human histamine H4 receptor ChemMedChem 4 2009 820 827
43. R.A. Smits Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo J. Med. Chem. 51 2008 2457 2467
44. J. Barker Integrating HTS and fragment-based drug discovery Drug Discov. World Summer 2008 67 73
45. K. Fukuzawa Ab initio quantum mechanical study of the binding energies of human estrogen receptor alpha with its ligands: an application of fragment molecular orbital method J. Comp. Chem. 26 2005 1 10
46. D.G. Fedorov, and K. Kitaura Extending the power of quantum chemistry to large systems with the fragment molecular orbital method J. Phys. Chem. A 111 2007 6904 6914
47. M. Ito Ab initio fragment molecular orbital study of molecular interactions in liganded retinoid X receptor: specification of residues associated with ligand inducible information transmission J. Phys. Chem. B 112 2008 12081 12094
48. Y.N. Imai Cl-π interactions in protein-ligand complexes Protein Sci. 17 2008 1129 1137